REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19-Reference-Cited by-同舟云学术

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Published:2021-12-02 Issue:23 Volume:385 Page:e81
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Weinreich David M.¹,Sivapalasingam Sumathi¹,Norton Thomas¹,Ali Shazia¹,Gao Haitao¹,Bhore Rafia¹,Xiao Jing¹,Hooper Andrea T.¹,Hamilton Jennifer D.¹,Musser Bret J.¹,Rofail Diana¹,Hussein Mohamed¹,Im Joseph¹,Atmodjo Dominique Y.¹,Perry Christina¹,Pan Cynthia¹,Mahmood Adnan¹,Hosain Romana¹,Davis John D.¹^ORCID,Turner Kenneth C.¹,Baum Alina¹,Kyratsous Christos A.¹,Kim Yunji¹,Cook Amanda¹,Kampman Wendy¹,Roque-Guerrero Lilia¹,Acloque Gerard¹,Aazami Hessam¹,Cannon Kevin¹,Simón-Campos J. Abraham¹,Bocchini Joseph A.¹,Kowal Bari¹,DiCioccio A. Thomas¹,Soo Yuhwen¹,Geba Gregory P.¹,Stahl Neil¹,Lipsich Leah¹,Braunstein Ned¹,Herman Gary¹,Yancopoulos George D.¹

Affiliation:

1. From Regeneron Pharmaceuticals, Tarrytown (D.M.W., T.N., S.A., H.G., R.B., J.X., A.T.H., J.D.H., B.J.M., D.R., M.H., J.I., D.Y.A., C. Perry, C. Pan, A.M., R.H., J.D.D., K.C.T., A.B., C.A.K., Y.K., A.C., W.K., B.K., A.T.D., Y. S., G.P.G., N.S., L.L., N.B., G.H., G.D.Y.) and Excision BioTherapeutics, New York (S.S.) — both in New York; Bio-Medical Research (L.R.-G.) and Universal Medical and Research Center (G.A.) — both in Miami; Hope Clinical Research, Canoga Park, CA (H.A.); PMG Research of Wilmington,...

Funder

Regeneron Pharmaceuticals

Biomedical Advanced Research and Development Authority of the Department of Health and Human Services

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2108163

Cited by 763 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control;Signal Transduction and Targeted Therapy;2024-09-11

2. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV);LANCET INFECT DIS;2024

3. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial;The Lancet Infectious Diseases;2024-09

4. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV);The Lancet Infectious Diseases;2024-09

5. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02